A self-assembling peptide acting as an immune adjuvant

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 2, 2010, Pages 622-627

  Rudra, Jai S ^a   Tian, Ye F ^a,b   Jung, Jangwook P ^a   Collier, Joel H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Illinois Institute of Technology   (United States)

Author keywords

Biomaterial; Epitope; Nanofiber; Self assembly; Vaccine

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; PEPTIDE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FREUND'S ADJUVANT; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOFIBERS; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; T-LYMPHOCYTES; TISSUE ENGINEERING;

MUS;

EID: 76249096897     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912124107     Document Type: Article

References (48)

1. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminum. Nat Rev Immunol, 9:287-293.
2. Wendorf J, et al. (2006) A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci, 95:2738-2750.
3. Daftarian P, et al. (2006) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine, 24:5235-5244.
4. Ishii KJ, Akira S (2007) Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol, 27:363-371.
5. Maraskovsky E, et al. (2009) Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol, 87:371-376.
6. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol, 169:3914-3919.
7. Sun HX, Xie Y, Ye YP (2009) Advances in saponin-based adjuvants. Vaccine, 27:1787-1796.
8. Lambrecht BN, Kool M, Willart MA, Hammad H (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol, 21:23-29.
9. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov, 6:404-414.
10. Bettahi I, et al. (2009) Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother, 58:187-200.
11. Cao CH, Lin XY, Wahi MM, Jackson EA, Potter H (2008) Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. BMC Neurosci, 9:25.
12. Toth I, Simerska P, Fujita Y (2008) Recent advances in design and synthesis of self-adjuvanting lipopeptide vaccines. Int J Pept Res Ther, 14:333-340.
13. Lutolf MP, Hubbell JA (2005) Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol, 23:47-55.
14. Place ES, Evans ND, Stevens MM (2009) Complexity in biomaterials for tissue engineering. Nat Mater, 8:457-470.
15. Silva GA, et al. (2004) Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science, 303:1352-1355.
16. Jung JP, et al. (2009) Co-assembling peptides as defined matrices for endothelial cells. Biomaterials, 30:2400-2410.
17. Collier JH (2008) Modular self-assembling biomaterials for directing cellular responses. Soft Matter, 4:2310-2315.
18. Davis ME, et al. (2005) Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation, 111:442-450.
19. Tysseling-Mattiace VM, et al. (2008) Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. J Neurosci, 28:3814-3823.
20. Genove E, Shen C, Zhang S, Semino CE (2005) The effect of functionalized self-assembling peptide scaffolds on human aortic endothelial cell function. Biomaterials, 26:3341-3351.
21. Horii A, Wang X, Gelain F, Zhang S (2007) Biological designer self-assembling peptide nanofiber scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration. PLoS ONE, 2:e190.
22. Collier JH, Messersmith PB (2003) Enzymatic modification of self-assembled peptide structures with tissue transglutaminase. Bioconjugate Chem, 14:748-755.
23. Jung JP, Jones JL, Cronier SA, Collier JH (2008) Modulating the mechanical properties of self-assembled peptide hydrogels via native chemical ligation. Biomaterials, 29:2143-2151.
24. Holmes TC, et al. (2000) Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci USA, 97:6728-6733.
25. Aggeli A, et al. (1997) Responsive gels formed by the spontaneous self-assembly of peptides into polymeric beta-sheet tapes. Nature, 386:259-262.
26. Gras SL, et al. (2008) Functionalised amyloid fibrils for roles in cell adhesion. Biomaterials, 29:1553-1562.
27. Schneider JP, et al. (2002) Responsive hydrogels from the intramolecular folding and self-assembly of a designed peptide. J Am Chem Soc, 124:15030-15037.
28. Hartgerink JD, Beniash E, Stupp SI (2001) Self-assembly and mineralization of peptide-amphiphile nanofibers. Science, 294:1684-1688.
29. Zhou M, et al. (2009) Self-assembled peptide-based hydrogels as scaffolds for anchorage-dependent cells. Biomaterials, 30:2523-2530.
30. Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT (2006) Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest, 116:237-248.
31. Dubois G, et al. (2008) Self-assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. J Biomed Mater Res B Appl Biomater, 87:222-228.
32. Guler MO, et al. (2006) Presentation of RGDS epitopes on self-assembled nanofibers of branched peptide amphiphiles. Biomacromolecules, 7:1855-1863.
33. Riley JM, Aggeli A, Koopmans RJ, McPherson MJ (2009) Bioproduction and characterization of a pH responsive self-assembling peptide. Biotechnol Bioeng, 103:241-251.
34. Yang M, Mine Y (2009) Novel T-cell epitopes of ovalbumin in BALB/c mouse: Potential for peptide-immunotherapy. Biochem Biophys Res Commun, 378:203-208.
35. McKee AS, Munks MW, Marrack P (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity, 27:687-690.
36. Carcaboso AM, et al. (2004) Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: Single intradermal administration. Pharm Res, 21:121-126.
37. Reddy ST, et al. (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol, 25:1159-1164.
38. Puffer EB, Pontrello JK, Hollenbeck JJ, Kink JA, Kiessling LL (2007) Activating B cell signaling with defined multivalent ligands. ACS Chem Biol, 2:252-262.
39. Ilyinskii PO, Thoidis G, Sherman MY, Shneider A (2008) Adjuvant potential of aggregate-forming polyglutamine domains. Vaccine, 26:3223-3226.
40. Fowler DM, Koulov AV, Balch WE, Kelly JW (2007) Functional amyloid-from bacteria to humans. Trends Biochem Sci, 32:217-224.
41. Jung JP, Gasiorowski JZ, Collier JH (2010) Fibrillar peptide gels in biotechnology and biomedicine. Biopolymers, in press.
42. Mond JJ, Lees A, Snapper CM (1995) T cell-independent antigens type 2. Annu Rev Immunol, 13:655-692.
43. Wen L, et al. (1994) Immunoglobulin-synthesis and generalized autoimmunity in mice congenitally deficient in alpha-beta(+)T cells. Nature, 369:654-658.
44. Test ST, Mitsuyoshi J, Connolly CC, Lucas AH (2001) Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun, 69:3031-3040.
45. Dintzis HM, Dintzis RZ, Vogelstein B (1976) Molecular determinants of immunogenicity-immunon model of immune-response. Proc Natl Acad Sci USA, 73:3671-3675.
46. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ (2000) B-cell activation by T-cell independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev, 176:154-170.
47. Jones KS (2008) Biomaterials as vaccine adjuvants. Biotechnol Prog, 24:807-814.
48. Sefton MV, Babensee JE, Woodhouse KA (2008) Innate and adaptive immune responses in tissue engineering. Semin Immunol, 20:83-85.